Dr Hafiz Abdul-Aziz

Postdoctoral Research Fellow

UQ Centre for Clinical Research
Faculty of Medicine


Dr. Hafiz Abdul–Aziz is currently a research fellow at the Burns, Trauma and Critical Care Research Centre (BTCCRC) and Centre for Research Excellence for Redefining Antimicrobial Use to Reduce Resistance (CRE REDUCE) at the University of Queensland, Australia. Hafiz is a clinical pharmacist with a strong interest in clinical research, particularly those involving multi-centre and multi-national collaborations. Hafiz received his Bachelor of Pharmacy and Master of Clinical Pharmacy degrees from Malaysia, prior to completing his PhD at the University of Queensland in 2016. Hafiz’s doctoral thesis was on pharmacokinetic/pharmacodynamic (PK/PD)-optimised beta-lactam dosing in critically ill patients.

His main research theme is primarily centred on finding novel solutions to optimise and personalise antimicrobial dosing in special patient populations, particularly in critically ill patients in the intensive care unit (ICU). Hafiz also believes that precision-based antibiotic dosing in the ICU can be achieved by integrating the use of dosing software and therapeutic drug monitoring into daily clinical practice. Hafiz has extensive experience in designing and conducting multi-centre/multi-national clinical pharmacokinetic studies in ICUs across Australia, Belgium, France, Indonesia, Malaysia, New Zealand, South Korea and Switzerland.


  • Doctor of Philosophy, The University of Queensland


  • Dhaese, Sofie, Heffernan, Aaron, Liu, David, Abdul-Aziz, Mohd Hafiz, Stove, Veronique, Tam, Vincent H., Lipman, Jeffrey, Roberts, Jason A. and De Waele, Jan J. (2020). Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. Clinical Pharmacokinetics doi: 10.1007/s40262-020-00919-6

  • Chai, Ming G., Cotta, Menino O., Abdul-Aziz, Mohd H. and Roberts, Jason A. (2020). What are the current approaches to optimising antimicrobial dosing in the intensive care unit?. Pharmaceutics, 12 (7) 638, 1-22. doi: 10.3390/pharmaceutics12070638

  • Abdul-Aziz, Mohd H., Alffenaar, Jan-Willem C., Bassetti, Matteo, Bracht, Hendrik, Dimopoulos, George, Marriott, Deborah, Neely, Michael N., Paiva, Jose-Artur, Pea, Federico, Sjovall, Fredrik, Timsit, Jean F., Udy, Andrew A., Wicha, Sebastian G., Zeitlinger, Markus, De Waele, Jan J., Roberts, Jason A., the Infection Section of European Society of Intensive Care Medicine (ESICM), Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC) (2020). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. Intensive Care Medicine, 46 (6), 1127-1153. doi: 10.1007/s00134-020-06050-1

View all Publications


  • Master Philosophy

  • Doctor Philosophy

  • Doctor Philosophy

View all Supervision


Book Chapter

  • Jamal, Janattul-Ain, Abdul-Aziz, Mohd-Hafiz, Levkovich, Bianca and Roberts, Jason A. (2019). Clinical pharmacy considerations in ICU. Encyclopedia of pharmacy practice and clinical pharmacy. (pp. 849-865) edited by Zaheer-Ud-Din Babar. Oxford, United Kingdom: Elsevier. doi: 10.1016/B978-0-12-812735-3.00576-8

  • Abdul-Aziz, M. H., Shekar, Kiran and Roberts, Jason A. (2017). Antibiotic dosing during extracorporeal membrane oxygenation. Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill. (pp. 151-171) Gateway East, Singapore: Springer Singapore. doi: 10.1007/978-981-10-5336-8_8

Journal Article

Conference Publication

Other Outputs

PhD and MPhil Supervision

Current Supervision

  • Master Philosophy — Associate Advisor

  • Doctor Philosophy — Associate Advisor

  • Doctor Philosophy — Associate Advisor

    Other advisors: